TY - JOUR
T1 - Adjuvant chemotherapy for soft tissue sarcomas
T2 - a 10-year mono-institutional experience
AU - Brunello, Antonella
AU - Rizzato, Mario Domenico
AU - Rastrelli, Marco
AU - Roma, Anna
AU - Maruzzo, Marco
AU - Basso, Umberto
AU - Fiduccia, Pasquale
AU - Buzzaccarini, M. S.
AU - Scarzello, Giovanni
AU - Rossi, Carlo Riccardo
AU - Zagonel, Vittorina
PY - 2016/3/1
Y1 - 2016/3/1
N2 - Purpose: The role of adjuvant chemotherapy (ACT) for soft tissue sarcomas (STS) is not standard practice. We investigated effectiveness and tolerability of ACT in patients (pts) with operated high-risk STS in clinical practice. Methods: Medical records of pts with localized STS referred to Istituto Oncologico Veneto, Padova, from January 1, 2003 to July 07, 2012 were reviewed. Data were collected for pts with high-risk STS (size ≥5 cm, high grade and stage III). For those who received ACT, regimens used, drug doses, number of cycles, toxicity, and reasons for dose reduction or treatment interruption were recorded. Disease-free survival (DFS) and overall survival (OS) were calculated with the Kaplan–Meier method. Results: Out of 96 eligible pts, median age 62 years, 36 received ACT after loco-regional treatment. Median DFS was 29.6 months (95 % CI 13.2–46.0) in pts receiving ACT and 7.8 months (95 % CI 3.9–11.7) in untreated pts (p
AB - Purpose: The role of adjuvant chemotherapy (ACT) for soft tissue sarcomas (STS) is not standard practice. We investigated effectiveness and tolerability of ACT in patients (pts) with operated high-risk STS in clinical practice. Methods: Medical records of pts with localized STS referred to Istituto Oncologico Veneto, Padova, from January 1, 2003 to July 07, 2012 were reviewed. Data were collected for pts with high-risk STS (size ≥5 cm, high grade and stage III). For those who received ACT, regimens used, drug doses, number of cycles, toxicity, and reasons for dose reduction or treatment interruption were recorded. Disease-free survival (DFS) and overall survival (OS) were calculated with the Kaplan–Meier method. Results: Out of 96 eligible pts, median age 62 years, 36 received ACT after loco-regional treatment. Median DFS was 29.6 months (95 % CI 13.2–46.0) in pts receiving ACT and 7.8 months (95 % CI 3.9–11.7) in untreated pts (p
KW - Adjuvant
KW - Chemotherapy
KW - Epirubicin
KW - High risk
KW - Ifosfamide
KW - Sarcoma
UR - http://www.scopus.com/inward/record.url?scp=84957957293&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84957957293&partnerID=8YFLogxK
U2 - 10.1007/s00432-015-2065-4
DO - 10.1007/s00432-015-2065-4
M3 - Article
AN - SCOPUS:84957957293
VL - 142
SP - 679
EP - 685
JO - Journal of Cancer Research and Clinical Oncology
JF - Journal of Cancer Research and Clinical Oncology
SN - 0171-5216
IS - 3
ER -